Adaptimmune

What a milestone! With the first commercial product order accepted, $ADAP looks forward to bringing this newly FDA-approved cell therapy to more patients in need. adaptimmune.com

#CellTherapy #Biotech #Innovation

ICYMI: $ADAP received @US_FDA accelerated approval for the first engineered cell therapy for the treatment of a solid tumor cancer. Announcement here: bit.ly/3AkpUJu
#celltherapy #biotech #oncology

#BreakingNews @GalapagosGlobal and
$ADAP sign clinical collaboration and exclusive option to license agreement for TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications. bit.ly/4aMsKnc
A live webcast will be held on Friday, May 31st at 8am ET. Live webcast and replay can be accessed at bit.ly/3Rv6Jmn

Today $ADAP reported financial results for Q4 and full year ended Dec. 31, 2023, and provided a business update on the progress made in establishing our sarcoma franchise. Release: bit.ly/48GMojA Call replay: bit.ly/4a0DfmZ #biotech #celltherapy #sarcoma

Please join us in welcoming back Cintia Piccina as $ADAP Chief Commercial Officer! Effective March 18, 2024, Cintia returns to lead a rapidly expanding commercial team as it prepares for the launch of afami-cel which, once approved, will be the first engineered TCR T-cell therapy on the market targeting solid tumors. #celltherapy #leadership